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Abstract
Roundup Ready soy contains the CP4-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein. Serum IgE from two distinct populations of soy-allergic patients were recruited to determine their IgE-binding specificity. One population consisted of 10
adult patients from Europe, whose primary diagnosis was soy food allergy with some also having mite allergy. In addition, 6 primarily mite-allergic, 6 food-allergic (celery, carrot, milk, shrimp, walnut, and apple), and 5 non-allergic patients were tested. Another population consisted of 13 children from Korea, whose primary diagnosis was atopic dermatitis and secondarily soy and egg
sensitization. In addition, 11 non-allergic patients were tested. Each patient population was extensively characterized with respect
to clinical symptoms, specific IgE (CAP) scores, and total IgE. Immunoblots and ELISA assays were developed using serum IgE from
these patients and soy extracts, CP4 EPSPS, rice extract, ovalbumin, rubisco, purified major peanut allergen Ara h 2, the putative
soy allergen Gly m Bd 30k and mite allergen Der f 2 proteins as the intended targets. Immunoblot results indicated that soy-allergic patients bound soy extracts but did not specifically bind rubisco or CP4 EPSPS. ELISA results were in general agreement with
the immunoblot results except that rubisco bound significant quantities of serum IgE from some patients. These results indicate
that the CP4 EPSPS protein does not bind significant quantities of IgE from two geographically distinct sensitive populations and
there is no evidence for an increased allergenic potential of this biotech protein.
Keywords: Atopic, CP4 EPSPS, Food allergy, IgE, Soy allergy
Abbreviations: CP4 EPSPS = CP4-enolpyruvylshikimate-3-phosphate synthase; GM = genetically modified

1 Introduction

a common soil-borne bacterium that produces the CP4enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS)
protein [2]. The CP4 EPSPS protein produced in Roundup
Ready plants is functionally identical to endogenous
plant EPSPS enzymes with the exception that CP4 EPSPS naturally displays reduced affinity for glyphosate relative to endogenous plant EPSPS [2]. The EPSPS enzyme
is part of the shikimate pathway that is involved in the
production of aromatic amino acids and other aromatic
compounds in plants [3]. When conventional plants are
treated with the herbicide glyphosate, the plants cannot
produce the aromatic amino acids needed to survive.

Genetically modified crops have been in the food supply
around the world for almost 10 years and are currently
planted on 222 million acres in 21 different countries [1].
In 2005, Roundup Ready soybean was planted on approximately 89% of the US Acreage (USDA-NASS, 2005.
http://usda.mannlib.cornell.edu/reports/nassr/field/ [Accessed: January 11, 2006]) and 60% of the global soybean areas [1], and is the most cultivated biotechnology product to date. Roundup Ready soybeans contain
the cp4 epsps gene from Agrobacterium spp. strain CP4,
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All proteins introduced into commercial genetically
engineered plants have undergone a rigorous safety assessment to ensure that there is a reasonable certainty
of no harm prior to their being placed on the market
for food and feed use. Protein safety is assessed by assays that are based on recommendations from a variety
of regulatory agencies including CODEX, US-FDA, and
EFSA. Evaluation of protein safety includes assessments
of a protein’s history of safe use, expression level, mode
of action, allergenicity, and acute toxicity. Results from
these assessments are used in a weight of evidence approach to determine if a protein is likely to pose a risk to
human or animal health.
The primary allergy risk to consumers from genetically modified crops may be placed into one of three
categories. The first, that represents the highest risk to
the allergic consumer is the transfer of a known allergen or IgE cross-reacting protein into a food crop. The
second category is the potential for an increase in the
endogenous allergenicity of an already allergenic crop
[4]. The last category involves expression of novel proteins that may become allergens in man [5]. In order to
mitigate the three categories of potential allergy risk associated with biotech crops, all genes introduced into
food crops undergo a series of tests that includes determination of the source of the introduced protein; any
significant similarity between the amino acid sequence
of the protein and known allergens; its susceptibility to
enzymatic degradation; and serum screens using documented sera from allergic individuals if the protein is
similar to known allergens or comes from an allergenic
source [6]. While there is detailed guidance on how to
perform bioinformatic analyses [7] and pepsin digestive fate studies [8], there is no consensus in the scientific community on the details of how to perform serum
studies for regulatory agencies. IgE-binding assays such
as radioallergosorbent tests (RAST; [9, 10]), ELISA [11],
or immunoblotting assays are available for this type of
testing. All these assays use IgE fractions of serum from
appropriately sensitized individuals. Sensitized individuals should be allergic to the food from which the transferred gene was derived as shown by a convincing clinical history [12] or positive responses in double-blind,
placebo controlled food challenges [9, 13].
In this study, our investigation focused on evaluating whether at-risk individuals, those with food allergy
to soybeans and plausible exposure to genetically modified (GM)-soybeans, have developed IgE specific to the
introduced CP4 EPSPS protein. Two different patient
populations were used: children with atopic dermatitis
secondarily diagnosed with soybean and other food allergies (Korean patients) and adult individuals with clinically documented soy allergy (European patients). For
this purpose, immunoblot and ELISA assays for specific
IgE were developed and validated, and control proteins
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were included in the screening to correlate the results obtained with CP4 EPSPS to immune responses to
known allergenic and non-allergenic proteins.
2 Materials and methods
2.1 Patient sera
2.1.1 Europe
A total of 22 sera of food-and mite-allergic patients as
well as 5 normal human sera were collected from European patients (see Table 1). Ten patients (21–57years old
at the time of sampling) with soy allergy were positive
in double blind placebo controlled food challenge (DBPCFC) or an open soy challenge, or had a convincing history of anaphylaxis after ingestion of soy protein. Sera
from other patients (18–60 years old at the time of sampling) with documented allergies to mite (6 patients),
celery, carrot, apple, milk, shrimp and walnut (1 patient
each) were utilized as atopic controls in this study. At the
time of assessment, allergic patients had total IgE levels
ranging from 21.5 to 2440 kU/L as measured by using
the Phadia CAP System (Phadia, Uppsala, Sweden).
2.1.2 Korea
A total of 13 sera of food-allergic patients and 11 normal
human sera were collected from Korean patients (see Table 2 for details). Ten patients (2–3 years old) exhibiting
severe atopic dermatitis with accompanying soy allergy
had a convincing history of allergic reactions to soy protein and high IgE levels to soy protein in the Phadia CAP
system. Sera from 3 egg-allergic patients (4 –8 years
old) also exhibiting severe atopic dermatitis were utilized in this study. At the time of the assessment, allergic
patients had total IgE levels ranging from 13.8 to 9250
kU/L as measured by using the Phadia CAP System.
2.2 Test proteins and extracts
2.2.1 Soy and rice extracts
Full-fat flour was extracted from four different commercial varieties of soybean (two Roundup Ready soy varieties and two non-transgenic soy varieties) using 1 X
PBS (NaCl 0.138 M, KCl 0.0027 M, with 0.05% Tween 20,
PBST) containing a protease inhibitor cocktail (Roche
Cat. # 1697498, 1 tablet/50 mL extraction buffer) using
a ratio of 1 g of flour to 10 mL of buffer. The suspensions
were mixed with slow agitation in closed sealed tubes
at 4°C for 2 h. The extracts were clarified by high-speed
centrifugation (100006or more). The clarified supernatants were passed through a 0.20-lm-sterile membrane
filter. The protein content of the extracts was determined
by a commercial dye-binding assay (Roth, Karlsruhe,
Germany) and aliquots were frozen at –20°C until use.
The rice extracts were prepared in similar manner.
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Table 1. European patients: chinical and serological characteristics
Patient
DOB
Allergy
Clinical *
DBPCFC**
CAPS (kU/L) 		
			
symptoms
(+/ – ) 				
					
Soy
Mite
Other
		
1
07/10/70
2
09/10/60
3
02/01/82
4
12/20/71
5
08/11/80
6
10/27/46
7
11/08/71
8
04/13/77
9
08/19/71
10
11/28/81
		
11
07/27/85
12
08/09/73
13
02/24/62
14
07/18/79
15
08/09/53
16
04/29/85
17
05/15/58
18
04/03/41
19
10/21/69
20
01/25/77
21
1968
22
1973
		
23
01/04/63
24
05/15/76
25
04/18/43
26
07/29/70
27
09/29/73

Soy

CAPS
(kU/L)
Gly m 4

		
OAS,N,F,BP
–
1 (0.54)
3 (3.98)
3 (3.98)
U
+
1 (0.63)
0 (<0.35) 		
0 (<0.35)
OAS,D,R
+
1 (0.51)
3 (10.4)
3 (10.4)
OAS,BI
+
2 (1.59)
3 (9.34)
3 (9.34)
OAS,D,N,E,AE
+
3 (9.91)
0 (<0.35) 		
0 (<0.35)
U,AE,BP,K
+
3 (5.05)
6 (100)
6 (100)
OAS,AE,D,E,BP
–
2 (2.10)
0 (<0.35) 		
0 (<0.35)
OAS,U
+
1 (0.65)
2 (0.92)
2 (0.92)
OAS
+
2 (2.12)
5 (77.7)
5 (77.7)
OAS
+
2 (1.34)
4 (31.23)
4 (31.23)
Mite
						
			
0 (<0.35)
3 (8.46)
		
			
1 (0.52)
6 (>100) 			
			
0 (<0.35)
3 (6.10)
		
			
0 (<0.35)
6 (>100) 			
			
0 (<0.35)
4 (21.3)
		
			
0 (<0.35)
4 (35.6)
		
Celery
OAS
+
1 (0.52)
3 (4.77)
Carrot
OAS
+
2 (0.83)
3 (10.3)
Milk
BP
–
0 (<0.35) 		
4 (19.9)
Shrimp
D,BP
–
0 (<0.35) 		
3 (12.2)
Walnut
U,GI
–
0 (<0.35) 		
4 (45.0)
Apple
OAS
–
0 (<0.35) 		
2 (2.93)
NA
						
			
0 (<0.35) 				
			
0 (<0.35) 				
			
0 (<0.35) 				
			
0 (<0.35) 				
			
0 (<0.35) 				

Total IgE
(kU/L)

137
72.2
21.5
175
161
2440
284
50.7
1435
1695
55.1
1245
300
1217
222
321
75.8
954
200
131
283
362
7.31
221
4.36
6.98
4.05

* AE, angioedema; Bl, blisters of the oral mucosa; BP, blood pressure drop; D, dyspnea; DOB, date of birth; E, Emesis; F, flush; GI, gastrointestinal
distress; K, conjunctivitis; N, nausea; NA, not allergic; OAS, oral allergy syndrome; R, rhinitis; U, urticaria.
** Double blind placebo controlled food challenge.

2.2.2 CP4 EPSPS proteins
Plant-and Escherichia coli-produced CP4 EPSPS proteins
were obtained from Monsanto Company (St. Louis, MO).
The plant-and E. coli-produced proteins were characterized and compared to each other with respect to their
identity, function, glycosylation status and purity. For
every criterion, the plant-and E. coli-produced proteins
met pre-set acceptance criteria for equivalence. The purity of the plant-produced protein was 85% and the purity of the E. coli-produced protein was 97% as assessed
by SDS-PAGE.

2.2.4 Rubisco and ovalbumin
The rubisco and ovalbumin proteins were obtained from
Sigma-Aldrich (St. Louis, MO). Rubisco was prepared
from spinach leaves and contained both the large and
small subunits, and was shipped as a partially purified
powder.

2.2.3 Der f 2 protein
The purified Der f 2 protein was purchased from Indoor
Biotechnologies (Charlottesville, VA). This protein was
purified from mites by affinity chromatography using an
anti-mite Group 2 mAb. The purity of the Der f 2 protein
was >95% according to the specifications provided by
the manufacturer.

2.3 SDS-PAGE and Western blotting
The extracts and purified proteins were separated by SDSPAGE according to Laemmli [15]. Extracts and proteins
were reduced by heating with 2x SDS-PAGE reducing
gel loading buffer (Laemmli Buffer, Bio-Rad cat. # 1610737; mixed 1:20 with 2-mercaptoethanol, Bio-Rad cat.
# 161-0710) and loaded into each well of a gradient gel

2.2.5 Ara h 2 and P34 (Gly m Bd 30 k) proteins
The peanut allergen Ara h 2 was prepared according to
the methods of Sen et al. [14]. E. coli-produced soy allergen P34 protein was obtained from Monsanto Company.
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Table 2. Korea patients: chinical and serological characteristics
Patient
DOB
Allergy
Clinical
DBPCFC
CAPS (kU/L)
			 symptoms*
(+/ – )		
					
Soy
		
258
12/03/01
259
07/17/02
377
06/20/02
466
09/29/01
537
08/16/02
571
05/27/02
622
10/17/01
664
11/23/02
733
04/18/03
815
06/21/02
		
86
03/18/97
208
04/14/01
414
01/30/00
		
13
03/01/01
14
08/03/00
17
10/25/03
20
07/10/89
21
09/02/03
22
01/30/00
25
08/30/02
26
01/07/04
27
10/10/03
30
09/02/97
31
04/26/91

Total IgE
		
Egg
Milk

Soy

				
AD,E,I
–
>100
>100
>100
AD,E,I
–
27.1
>100
74.4
AD,E,I
–
0.91
22
2.3
AD,E,I
–
14.4
65.9
1.96
AD,E,I
–
2.45
15.3
0.75
AD,E,I
–
65
>100
44.6
AD,E,I
–
>100
51.2
58.9
AD,E,I
–
4.99
7.89
0.46
AD,E,I
–
7.14
0
0
AD,E,I
–
>100
63.4
73.8
Egg
				
AD,BA
–
0
4.74
0
AD
–
0
>100
38
AD
–
0
>100
0
NA
				
			
0 			
			
0 			
			
0 			
			
0 			
			
0 			
			
0 			
			
0 			
			
0 			
			
0 			
			
0 			
			
0 			

(kU/L)

9250
2454
639
424
91.7
2072
721
331
13.8
2495
1569
699
381

* AD, atopic dermatitis; BA, bronchial asthma; DOB, date of birth; E, erythema; I, itching; NA, not allergic.

(10–20% Tris-Glycine gels, 1.0 mm × 15 wells, Novex precast gel; Invitrogen cat. # EC61355BOX). Precision Plus
Protein Standards (Bio-Rad, product # 161-0374) were
used as molecular weight markers to estimate protein
size. The separated proteins were transferred onto 0.45μm pore-sized PVDF (polyvinylidene fluoride) membrane (Sigma, P-2813) by means of the tank-blotting
method using a Hoe-fer transfer system with a cooling
unit (Hoefer® TE22, Amersham Bioscience).
Immunoblots were pre-incubated for 1 h at room
temperature with blocking reagent (PBST with 2% nonfat dry milk, NFDM) and then incubated overnight with
allergic and non-allergic sera diluted 1:10 v/v in blocking
reagent. Unbound IgE was removed by repeated rinses
with PBST. For detection of bound IgE the membranes
were incubated with biotin-labeled goat polyclonal IgGanti-human IgE (KPL, Gaithersburg, MD), followed by
washing and then incubation in NeutrAvidin-HRP (Pierce
Biotechnology, Rockford, IL). Detection was achieved using ECL (enhanced chemiluminescence; Amersham, or
Supersignal from Pierce), with multiple exposure times
per membrane to provide optimal signal to noise ratio
on the X-ray films. As a control, one membrane was incubated with the secondary antibody and ECL detection,
but without human serum to evaluate the specificity of

the detection system.
In some cases, inhibition experiments were performed
by incubating serum samples with soluble inhibitor for
approximately one hour before adding to pre-blocked
membranes. Inhibitor proteins were diluted in 2% NFDM
so that the final concentration of inhibitor, as incubated
with 1:10 diluted serum, would be 50 μg of inhibitor/mL
for CP4 EPSPS, rubisco and Ara h 2 and 500 μg of inhibitor/mL when using non-GMO or Roundup Ready soy
extract. Immunoblot incubation and detection were performed as described above.
2.4 IgE ELISA assay
Extracts and target proteins (pool of the two Roundup
Ready soy extracts, rubisco, ovalbumin and CP4 EPSPS
for the Korean population; for the European sera, ovalbumin was replaced with Der f 2) were diluted in pH 9.6
carbonate buffer to coating concentrations of 10 μg/mL
for extracts and 2 lg/mL for pure proteins and incubated
in microtiter plates overnight at 4°C in a humidity chamber to coat the wells. The coating solution was removed
by washing with PBST and nonspecific binding was
blocked with 2% NFDM in PBST. Serum samples were diluted 1:20 v/v in blocking buffer (at room temperature)
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160 min prior to addition to aspirated sample wells.
Plates were incubated for 2 h in a humidity chamber at
room temperature. Wells were washed three times with
PBST before the addition of biotinylated goat anti-IgE
(KPL) which was diluted 1:4000 v/v in PBST. Plates were
incubated for 160 min at room temperature and then
washed three times with PBST. NeutrAvidin-HRP (Pierce
Biotechnology) was diluted 1:8000 v/v in PBST, added to
sample wells, and incubated for 60 min at room temperature. Plates were washed three times with PBST before
addition of 100 μL substrate tetramethylbenzidine (TMB)
from KPL at room temperature. Reactions were stopped
after 10 min of incubation at room temperature by addition of 50 μL 6N sulfuric acid and the OD were read at
450 nm by a microplate reader.

3 Results
3.1 Patients and sera characteristics
The soy-allergic patients tested in this study represent
two distinct populations that have very different clinical presentations. The European patient population consisted of adults ranging in age from 18 –60 years old at
the time of sampling that presented with a wide variety of clinical symptoms after ingestion of soy (Table 1).
Their total IgE levels ranged from 21.5 –2440 kU/L with
a population mean of 647 kU/L. The soy CAP values for
these patients ranged from 1–3 with a population mean
of 2.4 kU/L. This low soy CAP value for soy-allergic patients is, at least partly, due to the exclusion of a major
soy allergen from the CAP assay that these patients recognize (Gly m 4) [16, 17]. When tested on recombinant
Gly m 4 CAP, seven out of ten patients were clearly positive with specific IgE levels of up to 100 kU/L and a mean
value of 33.4 kU/L for the positive patients (Table 1).
In contrast, the Korean patient population consisted of
children ranging in age from 2 –3 years old at the time
of sampling that presented with clinical symptoms of
atopic dermatitis that were secondarily diagnosed with
soy allergy from clinical histories (Table 2). Their total IgE
levels were much higher than in the European patient
population ranging from 13.8–9250 kU/L with a population mean of 1849 kU/L. The soy CAP values for these
patients were also much higher than the European patient population ranging from 0.91–100 kU/L with a
population mean of 42.2. In addition, many of the Korean patients showed significant CAP values to both egg
and milk allergens (Table 2).
The control for the European population represented
three different patient groups. One group consisted of
6 patients with mite allergy, 6 patients with food allergy
but not soy-allergic, and 5 non-allergic patients. Total IgE
levels for the mite-allergic patients ranged from 55.1–
1245 kU/L, for the food but not soy-allergic patients from

75.8–954 kU/L, and the non-allergic patients from 4.05 –
221 kU/L (Table 1). The control for the Korean population
represented two different patient groups. One group consisted of 3 patients with atopic dermatitis that were secondarily diagnosed with egg allergy from clinical histories and 11 non-allergic patients. Total IgE levels for the
atopic dermatitis patients secondarily diagnosed with egg
allergy ranged from 381–1569 kU/L. Total IgE was not determined for the non-allergic patients (Table 2).
3.2 IgE immunoblot analysis
A goat anti-CP4 EPSPS antibody was used to probe PVDF
membranes loaded with E. coli and plant expressed CP4
EPSPS, the mite allergen Der f 2, the major peanut allergen Ara h2, rubisco, ovalbumin, extracts from two
Roundup Ready soy varieties and two non-transgenic
varieties, as well as rice extract (Fig. 1). As expected, the
CP4 EPSPS protein was detected in the transgenic soy extract lanes and those lanes loaded with CP4 EPSPS protein standard. The immuno-detectable level of CP4 EPSPS
in GM soybean was approximately equivalent to the signal visible in the 40 ng/lane sample of E. coli produced
protein and markedly below the 400 ng/lane sample (Fig.
1), demonstrating the relevance of loading purified sample at 40 ng as representative for soybean loading for human IgE assays. An example of the IgE immunoblot results is indicated in Fig. 2. In all cases, the patient sera
reacted against positive control extracts and allergens as
expected. For example, the European soy-allergic patients
had IgE that recognized protein bands in soy extracts that
ranged in molecular weight from <10 kDa to >75 kDa.
There was also significant cross-reactivity with rice extract
proteins observed (Fig. 2). Similarly, the Korean patients
with atopic dermatitis secondarily diagnosed with soy allergy also recognized a wide range of soy proteins (<10–
75 kDa) with significant cross-reactivity noted for a variety of other proteins including ovalbumin, rubisco and
rice extracts (data not shown). No significant difference in
binding to extracts of wild-type versus GM soybean was
observed with any of the allergic patient sera.
One European soy-allergic patient serum (#8) and 2
Korean atopic dermatitis patient secondarily diagnosed
with soy allergy (537, 622) initially reacted with the pure
transgenic protein, CP4 EPSPS (Fig. 3) on long exposures of the film. The intensity of binding was not strong
(based on 40 ng loading equivalence to soybean samples) and was obvious in serum that bound to several
proteins in soy and rice extracts. In order to determine if
these sera contained IgE specific to CP4 EPSPS protein, a
Western blot inhibition experiment was performed (Fig.
4). In this experiment the CP4 EPSPS protein, rubisco,
non-transgenic soy extract and transgenic soy extract
were used separately as inhibitors to determine their effect on IgE binding. However, in these experiments, and

S e rum t es t i ng o f g e ne t i c a l l y m od i f i e d s oy b e a ns

951

Figure 1. CP4 EPSPS protein detection by goat anti-CP4 EPSPS antibodies. Proteins were electrophoresed, immunoblotted, and
then probed with anti-CP4 EPSPS antibodies to detect the CP4 ESPSPS proteins. Lane 1, molecular weight markers; Lane 2, rubisco
(400 ng); Lane 3, E. coli-produced CP4 EPSPS (400 ng); Lane 4, E. coli-produced CP4 EPSPS (40 ng); Lane 5, plant-produced CP4 EPSPS soybean (40 ng); Lane 6, Roundup Ready soy protein extract 1 (10μg); Lane 7, Non-GM soy protein extract 1(10 μg); Lane 8,
Non-GM soy protein extract 2 (10 μg); Lane 9, Roundup Ready soy extract 2 (10 μg); Lane 10, molecular weight markers; Lane 11,
Rice protein extract (10 μg); Lane 12, E. coli-produced soy allergen P34 (Gly m Bd 30 k) (400 ng); Lane 13, plant-produced peanut
allergen Ara h 2 (400ng); Lane 14, house dust mite allergen Der f 2 (400 ng); Lane 15, egg allergen ovalbumin Gal d 2 (400 ng).

Figure 2. Serum IgE binding to purified proteins and plant extracts. Proteins were separated by SDS-PAGE, immunoblotted, and
then probed with serum IgE from a European soy-allergic patient. Lane designations are the same as noted in the Fig. 1 legend.

Figure 3. Apparent IgE binding to purified CP4 EPSPS protein. Proteins were separated by SDS-PAGE, immunoblotted, and then
probed with serum IgE from European soy-allergic patient #8. Lane designations are the same as noted in the Fig. 1 legend.

several others, these sera failed to reproducibly bind to
the CP4 EPSPS protein but did bind to many of the soy
extract proteins. Furthermore, CP4 EPSPS protein had
no effect on IgE binding to the soy extract proteins but
the binding was markedly inhibited with nontransgenic
and transgenic soy extract proteins, suggesting that
the binding may be relatively nonspecific. In the case as
shown in Fig. 4, inhibition with the rubisco protein also
significantly reduced IgE to the soy extract proteins.
Since IgE binding to the CP4 EPSPS protein was not reproducible and binding to soy extract could be inhibited

by rubisco, it was concluded that there were no specific
IgE to the CP4 EPSPS protein.
3.3 ELISA analysis
Preliminary tests were used to determine the optimum concentrations of protein for coating of microtiter
plates, dilution of serum IgE and biotinylated anti-IgE,
and optimum times for incubation of reagents to maximize specific signals while minimizing nonspecific binding. Thereafter, all sera were tested according to the final
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Figure 4. IgE does not bind CP4 EPSPS protein reproducibly.
Proteins were separated by SDS-PAGE, immunoblotted, and
then probed with serum IgE from European soy-allergic patient
#8 that was unblocked or blocked with CP4 EPSPS, rubisco,
transgenic soy extract, or non-transgenic soy extract. Lane 1,
molecular weight markers, Lane 2, CP4 EPSPS E. coli (400 ng),
Lane 3, rubisco (400 ng), Lane 4, Roundup Ready (RR) soy extract (10 μg), Lane 5, non-GM soy extract (10 μg), Lane 6, peanut allergen Ara h 2 (400 ng), and Lane 7, egg allergen ovalbumin (Gal d 2) (400 ng).

protocol as specified in the Section 2. The values in Fig.
5 reflect the average of three independent wells without
the background subtracted from the raw OD readings.
All European patient serum IgE was used in ELISA assays with soy extract, rubisco, CP4 EPSPS or Der f 2 proteins as targets. Soy extract-binding values for the European soy-allergic patient population ranged from 0.44
to 0.82 with a population mean of 0.54. Mean IgE-binding values for this same population to rubisco, CP4 EPSPS, and Der f 2 were 0.16, 0.05, and 0.36, respectively.
Mean IgE-binding values for the mite allergic patients
showed significant binding to Der f 2 (1.21) as expected
with insignificant levels of IgE binding to rubisco (0.10)
and CP4 EPSPS (0.052). Mean IgE-binding values of the
mite allergic patients to soy extracts (0.44) were at the
lower range of the values obtained for the soy-allergic
patients.
Korean patient serum IgE was used in ELISA assays
with soy extract, rubisco, CP4 EPSPS or ovalbumin proteins as targets. Just as was observed for the soy CAP
values, ELISA results for the Korean patient population
were higher than those reported for the European patients. Soy extract-binding values for the Korean soy-allergic patient population ranged from 0.47 to 2.87 with
a population mean of 1.21. Mean IgE-binding values for
this same population to rubisco, CP4 EPSPS, and ovalbumin were 0.21, 0.06, and 1.31, respectively. Mean IgEbinding values for the atopic dermatitis patients that
were secondarily diagnosed with egg allergy showed

significant binding to ovalbumin (1.26) as expected; with
insignificant binding to rubisco (0.08), CP4 EPSPS (0.06)
and soy extract (0.53).

4 Discussion
The EPSPS family of enzymes is ubiquitous to plants and
microorganisms. EPSPS proteins have been isolated from
both sources, and their properties have been extensively
studied [18–22]. The EPSPS protein is absent in mammals, fish, birds, reptiles, and insects [19]. The bacterial
and plant enzymes are mono-functional with molecular
weights of 44–48 kDa [20]. EPSPS proteins catalyze the
transfer of the enolpyruvyl group from phosphoenolpyruvate (PEP) to the 5-hydroxyl of shikimate-3-phosphate (S3P), thereby yielding inorganic phosphate and
5-enolpyruvylshikimate3-phosphate (EPSP) [21]. Due to
the specificity of EPSPS for its substrates, the only known
catalytic product generated is EPSP, which is the penultimate product of the shikimic acid pathway. Shikimic acid
is a substrate for the biosynthesis of the aromatic amino
acids (phenylalanine, tryptophan and tyrosine) and other
aromatic molecules.
Roundup Ready soy contains the EPSPS gene derived from Agrobacterium spp. strain CP4 (cp4 epsps). The cp4 epsps coding sequence encodes a 47.6kDa EPSPS protein consisting of a single polypeptide
of 455 amino acids [2]. The CP4 EPSPS protein is structurally similar and functionally identical to endogenous
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Figure 5. ELISA results from Korean and
European soy-allergic patients.
(A) Histogram showing IgE binding
of Korean atopic dermatitis patients
secondarily diagnosed with soy allergy to different purified proteins and
extracts.
(B) Histogram showing IgE binding of
European soy-allergic patients to different purified proteins and extracts.

plant EPSPS enzymes, but has a much-reduced affinity
for glyphosate, the active ingredient in Roundup herbicides, relative to endogenous plant EPSPS [2]. In conventional plants, glyphosate binds to the endogenous
plant EPSPS enzyme and blocks the biosynthesis of shikimate-3-phosphate, thereby depriving plants of essential amino acids [22]. In Roundup Ready plants, which
are tolerant to the Roundup family of agricultural herbicides, requirements for aromatic amino acids and other
metabolites are met by the continued action of the CP4
EPSPS enzyme in the presence of glyphosate [2].
Harrison et al. [3] demonstrated the safety of the CP4
EPSPS protein according to the recommendations of
the Codex Alimentarius Commission [6]. Briefly, they
showed that the protein is from a non-allergenic source,
the protein does not represent a relatively large portion
of the total protein, the protein does not share structural similarities to known allergens or toxins based on
the amino acid sequence, the protein is unstable to digestion in simulated gastric fluid, and the protein is not
acutely toxic. Furthermore, others [23, 24] showed that
the endogenous allergenicity of GM soy containing this
gene is unchanged when compared with non-GM soy.
These characteristics ensure that the CP4 EPSPS does
not represent a known allergen and is unlikely to act as
a cross-reactive allergen. They also demonstrate that it

is unlikely the transfer of the gene altered the endogenous allergenicity of soy. The data obtained by IgE testing of extracts of GM and non-GM soy in this study confirm and underline these findings. Studies designed to
determine whether the endogenous allergenicity of a
GM crop has been modified when compared to its nonGM counterpart have repeatedly shown no change in
IgE-binding capacity. Perhaps this is not surprising given
that endogenous allergen expression would have to be
significantly up-regulated as a result of the gene transfer event. Given the large size of most plant genomes
and the very limited number of gene encoding allergens
the trans-gene would have to be inserted proximal to an
allergen gene in such a way as to up-regulate transcription. This seems like it would be an extremely rare event
and perhaps we should reconsider whether this study
brings any value to the allergy assessment process.
The studies mentioned above address two of the
categories of potential allergenic risk to public health
posed by genetically modified crops; transfer of a
known allergen or likely cross-reactive protein and the
potential increase in endogenous allergenicity of an already allergenic crop [4]. Recently, Batista et al. [25] attempted to test for evidence that CP4 EPSPS may have
sensitized consumers by performing a post-market serum study to address the third category of allergenic
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risk to public health; expression of a novel protein that
becomes an allergen. In their study serum IgE from a
wide variety of allergic patients were tested to determine if they developed IgE to proteins newly introduced
into food crops after having been exposed to them for
a long period. The patients had positive histories of
food allergy or inhalant allergy with the probability of
these individuals having eaten GM soy containing the
CP4 EPSPS protein near 100% based on the global distribution of GM soy containing CP4 EPSPS and ubiquitous use of soy protein in processed foods. Results from
their study showed that none of the patients tested had
detectable levels of IgE directed against the CP4 EPSPS
protein and that there were no discernable differences
between transgenic and non-transgenic extracts when
used in skin prick tests [25].
In contrast, the present study tested a more focused
study population that included soy-allergic patients
from Europe and atopic dermatitis patients that were
secondarily diagnosed with soy allergy from Korea as
the test groups. Even though the patient populations
tested in each of these studies were different there was
no significant IgE binding to the CP4 EPSPS protein. In
the IgE ELISA in which the proteins were tested under
non-denaturing conditions, CP4 EPSPS had the lowest
IgE-binding capacity of all antigens tested. Binding to
CP4 EPSPS was even lower than to rubisco, a ubiquitous
plant protein that has never been described as an allergen, though rubisco clearly bound IgE from some of our
study participants by ELISA (Fig. 5). In IgE Western blotting experiments, sera from three subjects showed weak
apparent binding to the biotech protein which could not,
however, be reproduced in subsequent experiments. In
attempts to confirm the specificity of the antibody binding, unspecific effects were observed with soy extracts,
CP4 EPSPS, and rubisco. In part these effects may be due
to low affinity binding to plant N-glycans (soybean extracts), but it is more likely that the high sensitivity of the
enzyme immunologic detection of the Western blots did
result in some unspecific binding only visible under the
denaturing conditions of the Western blot assay, but not
in the more physiological ELISA test. Therefore, we conclude that, 10 years after market introduction and consumption of Roundup Ready soy, our study revealed no
evidence for allergenicity of the heterologous protein
CP4 EPSPS.
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